Merck has agreed to acquire biopharmaceutical company Verona Pharma in a deal valued at $10bn. The acquisition will be made by the subsidiary of Merck, which is known as MSD outside of the US and Canada. The deal values London-based Verona at about $107 per American depository share,...

Sanofi announced the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a promising pipeline, and the expertise of a company specializing in systemic mastocytosis (SM), a rare immunological disease, and...

BioNTech announced a $1.25 billion all-stock acquisition of CureVac through a public exchange offer, offering $5.46 per CureVac share representing a 55% premium to strengthen its mRNA-based cancer immunotherapy capabilities. The strategic transaction will combine complementary mRNA...

Eli Lilly and Company and SiteOne Therapeutics, , a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, announced a definitive agreement for Lilly to acquire SiteOne “The global...

Sanofi has agreed to acquire Vigil Neuroscience in a $470m deal, nearly a year after investing an initial $40m in the company. The deal will see Sanofi acquire all outstanding common shares of US-based Vigil for $8 per share in cash at closing. Although Vigil has two candidates in...

Novo Holdings, a global investment firm focused on life sciences, has completed its previously announced acquisition of Catalent. Under private ownership, Catalent benefits from Novo Holdings’ significant resources, and is well-positioned to deliver unparalleled outcomes for...

AbbVie is paying $200 million to snap up Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune space. As part of the acquisition, the North Chicago-based Big Pharma will also dole out undisclosed interim payments. Shareholders of the...

GE HealthCare has acquired full ownership of a leading radiopharmaceutical firm Nihon Medi-Physics, that generated $183 million in revenue last year.  NMP’s product portfolio includes GE HealthCare radiopharmaceuticals delivered across neurology, cardiology and oncology. Among them...